Hepatitis B virus or Hepatitis C virus related liver cirrhosis
Conditions
Interventions
<
Group of CE-US>
screening by CE-US using Sonazoid(TM) in the postvascular phase every 3-5 months
<
Group of B-mode US>
screening by conventional B-mode US every 3-5 months
Sponsors
Japan Liver Oncology Group (JLOG)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Age over 20 2) HBV or HCV related liver cirrhosis 3) No history of HCC 4) Diagnosed as liver cirrhosis histologically or clinically Histologically confirmed by liver biopsy Confirmed by formula of diagnosing cirrhosis Radiological finding Finding of portal hypertension Platelet<130,000 5) Inpatient or outpatient 6) Patients who signed a written informed consent form
Exclusion criteria
Exclusion criteria: 1) History of hypersensitivity to egg yolk 2) Pregnant or lactating women and women who may be pregnant 3) Severe liver dysfunction(AST, ALT,or BIL level >10ULN 4) Associated with HCC 5) Paients receiving interferon 6) Age under 20 7) Judged by investigator not to be appropriate for inclusion in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Size of HCC which is detected first | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Time to detection of HCC 2) Number of HCC which is detected first 3) Stage of HCC which is detected first 4) The ability of definitive diagnosis of HCC 5) Sensitivity, Specificity and accuracy of the diagnosis of HCC 6) The improvement of prognosis of patients who are diagnosed in this study 7) The accumulated rate of detection of HCC | — |
Countries
Japan
Contacts
Public ContactKazuomi Ueshima
Kinki University School of Medicine Gastroenterology and Hepatology
Outcome results
None listed